Citation: | YUE Jing, KANG Jing, LI Guoyin. Influence of SLC16A Family on Clinical Features and Biological Behaviours of Lung Adenocarcinoma and Squamous Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 24-31. DOI: 10.3971/j.issn.1000-8578.2022.21.0700 |
To explore the relation between SLC16A family and clinical characteristics, biological behavior of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).
The expression of 14 members of the SLC16A family in LUAD tissues, LUSC tissues and normal tissues in TCGA database was analyzed by Wilcoxon signed rank sum test. Cox regression was used to evaluate the relation between the family and overall survival, progression-free survival of LUAD and LUSC patients. Logistic regression was used to evaluate the relation between the family and TNM, clinical stage of LUAD and LUSC patients. Principal component analysis was used to establish a Score-SLC16As that comprehensively reflected the family in LUAD and LUSC. ROC, Log rank analysis and univariate and multivariate Cox regression analyses were applied to evaluate the diagnostic effect and survival prediction function of Score-SLC16As on LUAD and LUSC respectively. GSEA was used to evaluate the biological significance of Score-SLC16As and CIBERSORT/Immune checkpoint clusters were used to assess the immune status of Score-SLC16As in LUAD and LUSC.
In LUAD and LUSC, most members of SLC16A family were differentially expressed and significantly correlated with survival prognosis. Score-SLC16As can clearly diagnose LUAD and LUSC, significantly predict survival prognosis, and can be used as an independent risk factor. Score-SLC16As is a risk factor for LUAD but a protective factor for LUSC. Score-SLC16As is closely related to tumor proliferation pathways and immune escape.
The SLC16A family is closely related to the clinical features and malignant biological behaviors of LUAD and LUSC.
Competing interests: The authors declare that they have no competing interests.
[1] |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
[2] |
Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis and Treatment[J]. Mayo Clin Proc, 2019, 94(8): 1623-1640. doi: 10.1016/j.mayocp.2019.01.013
|
[3] |
Bersani F, Morena D, Picca F, et al. Future perspectives from lung cancer pre-clinical models: new treatments are coming?[J]. Transl Lung Cancer Res, 2020, 9(6): 2629-2644. doi: 10.21037/tlcr-20-189
|
[4] |
Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression[J]. Science, 2020, 368(6487): eaaw5473. doi: 10.1126/science.aaw5473
|
[5] |
Kim J, DeBerardinis RJ. Mechanisms and Implications of Metabolic Heterogeneity in Cancer[J]. Cell Metab, 2019, 30(3): 434-446. doi: 10.1016/j.cmet.2019.08.013
|
[6] |
Kuo TC, Huang KY, Yang SC, et al. Monocarboxylate Transporter 4 Is a Therapeutic Target in Non-small Cell Lung Cancer with Aerobic Glycolysis Preference[J]. Mol Ther Oncolytics, 2020, 18: 189-201. doi: 10.1016/j.omto.2020.06.012
|
[7] |
Felmlee MA, Jones RS, Rodriguez-Cruz V, et al. Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease[J]. Pharmacol Rev, 2020, 72(2): 466-485. doi: 10.1124/pr.119.018762
|
[8] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
|
[9] |
Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22. doi: 10.1186/s40880-019-0368-6
|
[10] |
Chen R, Manochakian R, James L, et al. Emerging therapeutic agents for advanced non-small cell lung cancer[J]. J Hematol Oncol, 2020, 13(1): 58. doi: 10.1186/s13045-020-00881-7
|
[11] |
Doval DC, Desai CJ, Sahoo TP. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors[J]. Indian J Cancer, 2019, 56(Supplement): S23-S30. https://pubmed.ncbi.nlm.nih.gov/31793439/
|
[12] |
Kauffmann-Guerrero D, Kahnert K, Huber RM. Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer[J]. Drugs, 2021, 81(1): 87-100. doi: 10.1007/s40265-020-01445-2
|
[13] |
Remon J, Passiglia F, Ahn MJ, et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations[J]. J Thorac Oncol, 2020, 15(6): 914-947. doi: 10.1016/j.jtho.2020.03.006
|
[14] |
Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics[J]. J Hematol Oncol, 2019, 12(1): 92. doi: 10.1186/s13045-019-0779-5
|
[15] |
Bergers G, Fendt SM. The metabolism of cancer cells during metastasis[J]. Nat Rev Cancer, 2021, 21(3): 162-180. https://www.nature.com/articles/s41568-020-00320-2/email/correspondent/c1/new
|
[16] |
Fendt SM, Frezza C, Erez A. Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy[J]. Cancer Discov, 2020, 10(12): 1797-1807. doi: 10.1158/2159-8290.CD-20-0844
|
[17] |
Certo M, Tsai CH, Pucino V, et al. Lactate modulation of immune responses in inflammatory versus tumour microenvironments[J]. Nat Rev Immunol, 2021, 21(3): 151-161. https://pubmed.ncbi.nlm.nih.gov/32839570/
|
[18] |
Bosshart PD, Charles RP, Garibsingh RA, et al. SLC16 Family: From Atomic Structure to Human Disease[J]. Trends Biochem Sci, 2021, 46(1): 28-40. doi: 10.1016/j.tibs.2020.07.005
|